推荐应用
Fas (fibroblast associated; also known as APO-1 or CD95) is a member of the death receptor subfamily of the TNF receptor superfamily and is designated TNFRSF6. The human Fas precursor is 335 aa in length, and contains a 25 aa signal peptide, a 148 aa extracellular domain (ECD), a 17 aa transmembrane sequence, and a 145 aa cytoplasmic region. The ECD possesses three cysteine-rich TNFR repeats, while the cytoplasmic region contains one death domain (DD) that is required for the transduction of apoptotic signals (4). Human Fas ECD shares 55%, 58% 62% 63% and 64% aa sequence identity with mouse, rat, feline, bovine and porcine Fas ECD, respectively. A human Fas isoform of 314 aa that lacks the transmembrane sequence is secreted by resting lymphocytes, while isoforms of 149, 132, 103 and 86 aa that also lack the DD and show substitutions for parts of the TNFR repeats are less prominently expressed. All five isoforms block the extrinsic apoptosis pathway induced by Fas ligand binding. Fas ligand (FasL; also TNFSF6) is a type II transmembrane protein that belongs to the TNF family and is expressed on activated T-cells, NK cells, and cells found in immune privileged sites. Alternatively, FasL is also shed as a soluble form. Engagement of Fas induces oligomerization of preformed Fas trimers. This activated receptor complex recruits the adaptor molecule FADD to form the Death-Inducing Signaling Complex (DISC). Upon activation, caspases in the DISC initiate the apoptotic signaling cascade. Fas is prominent in epithelial cells, hepatocytes, activated mature lymphocytes, virus-transformed lymphocytes and tumor cells. It is an essential mediator in the activation-induced death of T lymphocytes that terminates the immune reaction.
高纯度、高活性、低内毒素、高批间一致性
产品数据
Tris-Bis PAGE

-25 ~ -15℃保存,收到货之后有效期1年。 复溶后, 无菌条件下,-85 ~ -65℃保存,3个月有效期。
【应用方向】HER2与HER3:ErbB受体家族协同靶向治疗的核心工具蛋白
162
2026-08-31
【应用方向】HER2:抗体药物研发的核心工具蛋白
169
2026-08-31
【应用方向】抗体药研发中常见靶点蛋白及其应用
214
2026-08-31
【应用方向】靶点蛋白在抗体药研发中的应用
160
2026-08-31
【应用方向】GPC3:HCC靶向治疗的核心靶点与药物研发探索
1983
2026-04-24
【应用方向】TROP2:从分子机制到实体瘤靶向治疗的研究进展
1934
2026-04-24
【应用方向】4-1BB-4-1BBL共刺激轴的T细胞活化机制
1175
2026-04-22
【应用方向】TNFR蛋白家族概述
1122
2026-04-21
【应用方向】Klotho蛋白:编织生命之线的抗衰老分子
1308
2026-04-20
【应用方向】药靶明星 | FGFRs家族蛋白解析
966
2026-04-20
【应用方向】解析Fc受体:抗体药物研发的核心靶点与评价基石
981
2026-04-20
【应用方向】FcγR家族:抗体药物研发的基石与核心靶点
1072
2026-04-20
【应用方向】CD47-SIRPα轴研究工具与药物开发应用
885
2026-04-20
【应用方向】HER2靶点蛋白:驱动肿瘤靶向治疗的核心力量
14650
2026-03-02
【技术讲解】细胞因子科学选型--常见问题解答
11258
2026-09-21





